In vitro and in vivo immunomodulatory activity of an N-9 arginyl hypoxanthine derivative (PCF-39)

  • Int J Immunopharmacol. 1987;9(6):659-67. doi: 10.1016/0192-0561(87)90036-1.
M Giovarelli  1 ,  R Arione ,  C Jemma ,  T Musso ,  G Benetton ,  G Forni ,  P Cornaglia-Ferraris
Affiliations
  • 1. Institute of Microbiology, University of Turin, Italy.
PMID: 3692639 DOI: 10.1016/0192-0561(87)90036-1
Abstract

A new synthetic derivative, N-alpha-5 (1,6-dihydro-6-oxo-9-purinyl) pentyloxy-carbonyl-L-arginine (PCF-39) has been evaluated in vitro and in vivo in order to clarify its immunopharmacologic profile. In vitro, PCF-39 did not modify spleen cell functions, whereas parenteral administration in mice of 2.5 and 25 mg/kg (50 and 500 micrograms/mouse) induced an increase in spleen and lymph node cellularity that resulted in a significant resistance to the growth of two distinct syngeneic transplanted Tumors. These in vivo findings show that PCF-39 is a potent immunotherapeutic agent with an antitumor effect.

Products